title: Quality of post-treatment surveillance of early stage breast cancer in Texas.
abstract: BACKGROUND
  Only annual mammography and physical examination are recommended for the post-treatment surveillance of early stage breast cancer.
  
  
  METHODS
  We used Texas Cancer Registry-Medicare linked data (2001-2007) to identify physician visits and use of mammography, magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) CT in patients ≥ 66 years old with ductal carcinoma in situ and stage I-III ductal carcinoma who underwent curative-intent operations. We also evaluated the trends in use of recommended and nonrecommended tests.
  
  
  RESULTS
  We identified 8,598 patients with resected ductal carcinoma in situ (37.3%) or invasive ductal cancer (62.7%). Breast-conserving therapy was performed in 59%. Only 55% saw a physician twice a year for 2 years and underwent annual mammography for 2 consecutive years in the surveillance period. Mammography use decreased from 81% in 2001 to 75% in 2007 (P < .0001), and breast MRI use rose from 0.5% to 7.0% (P < .0001). For asymptomatic patients, the use of CT/MRI of the abdomen, chest, and head was 27%, 23%, and 22%, and this slightly increased during the study period. There was a significant increase in PET/PET CT use, from 2% in 2001 to 9% in 2007 (P < .0001). There was a concomitant decrease in bone scan use from 21% in 2001 to 13% in 2007 (P < .0001).
  
  
  CONCLUSIONS
  Adherence to evidence-based guidelines has been substandard and the use of nonrecommended tests has persisted over the study period. The rise in PET use and attendant decrease in bone scan implicates a population receiving PET scan in lieu of bone scan for surveillance of asymptomatic metastatic disease. In an elderly population of breast cancer patients in Texas, these findings imply both underuse and overuse.
authors.affiliation: Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555-0541, USA.
authors.forename: Abhishek D
authors.initials: AD
authors.lastname: Parmar
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Sheffield
authors.forename: Gabriela M
authors.initials: GM
authors.lastname: Vargas
authors.forename: Yimei
authors.initials: Y
authors.lastname: Han
authors.forename: Celia
authors.initials: C
authors.lastname: Chao
authors.forename: Taylor S
authors.initials: TS
authors.lastname: Riall
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008327:Mammography; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
references.citation: Eur Radiol. 2011 Dec;21(12):2484-91
references.pmid: 21833567
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5091-7
references.pmid: 17033037
references.citation: Breast Cancer Res Treat. 2009 Apr;114(3):403-12
references.pmid: 18421576
references.citation: Breast Cancer Res Treat. 1984;4(4):303-7
references.pmid: 6518296
references.citation: Br J Cancer. 2007 Dec 17;97(12):1632-41
references.pmid: 18000508
references.citation: CMAJ. 1998 Feb 10;158 Suppl 3:S65-70
references.pmid: 9484280
references.citation: Breast Cancer Res Treat. 2009 Mar;114(1):169-78
references.pmid: 18368477
references.citation: Med Care. 2000 Mar;38(3):281-9
references.pmid: 10718353
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):663-70
references.pmid: 21947679
references.citation: Breast J. 2006 Jan-Feb;12(1):2-6
references.pmid: 16409580
references.citation: J Oncol Pract. 2010 Jul;6(4):174-81
references.pmid: 21037867
references.citation: J Clin Oncol. 1986 Mar;4(3):389-94
references.pmid: 3485185
references.citation: Cancer. 1985 Jan 1;55(1):202-5
references.pmid: 3965082
references.citation: Cancer. 1979 Mar;43(3):956-60
references.pmid: 427736
references.citation: Br J Radiol. 1992 Jan;65(769):30-2
references.pmid: 1486366
references.citation: JAMA. 1994 May 25;271(20):1593-7
references.pmid: 7848404
references.citation: N Engl J Med. 2002 Oct 17;347(16):1233-41
references.pmid: 12393820
references.citation: Breast. 2002 Jun;11(3):228-35
references.pmid: 14965672
references.citation: J Clin Oncol. 1997 Apr;15(4):1401-8
references.pmid: 9193332
references.citation: Med Care. 2001 Sep;39(9):945-55
references.pmid: 11502952
references.citation: Breast. 2002 Apr;11(2):163-9
references.pmid: 14965664
references.citation: Health Technol Assess. 2010 Oct;14(50):1-103
references.pmid: 21044553
references.citation: Breast. 2013 Jun;22(3):351-6
references.pmid: 22989668
references.citation: J Surg Oncol. 1987 Mar;34(3):194-7
references.pmid: 2434803
references.citation: J Natl Compr Canc Netw. 2009 Feb;7(2):122-92
references.pmid: 19200416
references.citation: J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96
references.pmid: 19930975
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1054-61
references.pmid: 19164212
references.citation: Cancer. 1980 Aug 15;46(4 Suppl):977-9
references.pmid: 7397676
references.citation: Br J Surg. 1989 Feb;76(2):187-90
references.pmid: 2702456
references.citation: J Surg Oncol. 1986 Jul;32(3):179-81
references.pmid: 3736055
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3001-6
references.pmid: 17548838
references.citation: JAMA. 1994 May 25;271(20):1587-92
references.pmid: 8182811